<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660461</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2016-004021-16</org_study_id>
    <secondary_id>FIM-PXE-2016-01</secondary_id>
    <nct_id>NCT04660461</nct_id>
  </id_info>
  <brief_title>Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)</brief_title>
  <acronym>FIMPXE2016-01</acronym>
  <official_title>Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol code and version: FIM-PXE-2016-01 Version 1.4&#xD;
&#xD;
      Trial title: &quot;Response to oral lansoprazole of inorganic pyrophosphate levels in patients&#xD;
      with Grönblad- Stranberg disease (Pseudoxanthoma Elasticum)&quot;&#xD;
&#xD;
      Trial design: Double-blind, placebo-controlled, randomised, two-stage crossover clinical&#xD;
      trial, with each patient serving as their own control and reducing the number of patients to&#xD;
      confirm our hypothesis.&#xD;
&#xD;
      Principal Investigator: Dr. Pedro Valdivielso Felices Participating centres Virgen de la&#xD;
      Victoria's Universitary Hospital in Malaga and Virgen de la Macarena's Universitary Hospital&#xD;
      in Seville.&#xD;
&#xD;
      Duration of the trial: 12 months Expected start date: December 2019 Objectives: Principal:To&#xD;
      verify the changes in plasma PPi, and the main molecules that regulate it (NPP1-3, TNAP)&#xD;
      after oral administration of lansoprazole in patients diagnosed with PXE.&#xD;
&#xD;
      Description of treatment:&#xD;
&#xD;
      Selection:20 patients who meet all the criteria for inclusion and none for exclusion.&#xD;
&#xD;
      Randomisation and 1st stage: Patients will receive lansoprazole 30mg/day or their placebo for&#xD;
      8 weeks.&#xD;
&#xD;
      Wash-out: After 8 weeks, all treatment will be suspended for 15 days. 2nd stage (crossed):&#xD;
      Treatment is crossed, each patient serves as his or her own control.&#xD;
&#xD;
      Evaluation variables:&#xD;
&#xD;
        1. Date of Birth&#xD;
&#xD;
        2. Sex.&#xD;
&#xD;
        3. Physical examination (anthropometry and vital signs)&#xD;
&#xD;
        4. Date of first symptom.&#xD;
&#xD;
        5. Date of final diagnosis&#xD;
&#xD;
        6. Ocular affectation (orange peel skin, complete striae angioides, lucentis, corrected&#xD;
           visual acuity, cataracts, intraocular pressure, fundus (vascular flow, optic nerve&#xD;
           drusen, retinal atrophy, neovascular membranes, macular thickness, colloid thickness).&#xD;
&#xD;
        7. Skin affectation (yellowish papules or plaques on the side of the neck or other areas of&#xD;
           flexure and lax skin).&#xD;
&#xD;
        8. Vascular affectation (intermittent claudication clinic, angina and/or episode of acute&#xD;
           myocardial infarction and/or non-embolic ischemic stroke, surgical or percutaneous&#xD;
           revascularisation, cardiac murmur,10.)&#xD;
&#xD;
        9. History of renal lithiasis, arterial hypertension, diabetes mellitus, treatments,&#xD;
           smoking and dyslipidemia.&#xD;
&#xD;
       10. Specific biochemical variables:&#xD;
&#xD;
      Inorganic pyrophosphate (IPP) NPP1 and NPP2.3: activity and mass concentration of the enzyme&#xD;
      Non-specific tissue alkaline phosphatase (NTAP) and PHA. Osteocalcin: To check possible side&#xD;
      effects on bone metabolism. 5'-Nucleotidas General analytical parameters (haemoglobin,&#xD;
      haematocrit, MVC, MHC, platelets, neutrophils, prothrombin activity, TPTA, thrombin time,&#xD;
      ferritin, PCR, glycaemia, urea, creatinine, cholesterol, triglycerides, HDL cholesterol, LDL&#xD;
      cholesterol, uric acid, calcium, phosphorus, alkaline phosphatase, PTH). By means of routine&#xD;
      clinical laboratory techniques. Number of patients: TOTAL : 20 patients(Competitive&#xD;
      recruitment)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">June 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Clinical trial, double blind, placebo controlled, randomized and crossed groups of patients in two stages, that receive a treatment with lansoprazole and placebo during 8 weeks with wash-ot period of 15 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The masking of the drug to produce the cecum will be carried out by the Pharmacy on University Hospital Virgen de la Macarena accredited by the AEMPS. The medication for this clinical trial will be prepared by the Pharmacy on University Hospital Virgen de la Macarena in Seville ; the lansoprazole capsules and their placebo will be re-encapsulated in larger ones to maintain the cecum. The proposed doses used are those used in mild/moderate gastro-oesophageal diseases</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in PPi,NPP1-3 and TNAP</measure>
    <time_frame>8 weeks, 18 weeks</time_frame>
    <description>changes in plasma PPi, and the main molecules that regulate it (NPP1-3, TNAP) after oral administration of lansoprazole in patients diagnosed with PXE</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)</condition>
  <arm_group>
    <arm_group_label>1. Randomized placebo-controlled, parallel-group study, crossover-design</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Randomized placebo-controlled, parallel-group study, crossover-design</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 30mg</intervention_name>
    <description>Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks</description>
    <arm_group_label>1. Randomized placebo-controlled, parallel-group study, crossover-design</arm_group_label>
    <arm_group_label>2. Randomized placebo-controlled, parallel-group study, crossover-design</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks</description>
    <arm_group_label>1. Randomized placebo-controlled, parallel-group study, crossover-design</arm_group_label>
    <arm_group_label>2. Randomized placebo-controlled, parallel-group study, crossover-design</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥18 years old&#xD;
&#xD;
          2. Patients diagnosed with PXE according to 2010 criteria by PLOMP et al.&#xD;
&#xD;
          3. At least, patients meet two of the following criteria:&#xD;
&#xD;
               1. Retinal lesions such as Orange peel and/or Angioid streaks&#xD;
&#xD;
               2. Skin lesions such as papules or yellowish plaques on the lateral face of the neck&#xD;
                  and / or flexures of the body (armpits, elbows, knees) or alterations in the skin&#xD;
                  biopsy with fragmentation and / or conglomerates of and / or calcification of the&#xD;
                  elastic fibers.&#xD;
&#xD;
               3. A pathogenic mutation of the two alleles of the ABCC6 gene.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal of informed consent.&#xD;
&#xD;
          2. Vegetarian diet or extreme diets.&#xD;
&#xD;
          3. Pregnancy or its intention during the months of the study.&#xD;
&#xD;
          4. Age &lt;18 years old&#xD;
&#xD;
          5. Known hypersensitivity to &quot;prazoles&quot; or proton pump inhibitors.&#xD;
&#xD;
          6. Intake of medications that may interfere with Lansoprazole and that cannot be&#xD;
             withdrawn or modified in its form of administration to avoid such interference.&#xD;
&#xD;
          7. Prior taking of proton pump inhibitors, except for a wash out period of 15 days if the&#xD;
             clinical situation of the patient allows it.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gloria Luque</last_name>
    <phone>951291977</phone>
    <email>gloria.luque@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Valdivieso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Valdivieso</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Carlos Carrillo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, Pasquali-Ronchetti I, Pope FM, Richards A, Terry S, Bercovitch L, de Paepe A, Boyd CD. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet. 2000 Jun;25(2):223-7.</citation>
    <PMID>10835642</PMID>
  </reference>
  <reference>
    <citation>Scheffer GL, Hu X, Pijnenborg AC, Wijnholds J, Bergen AA, Scheper RJ. MRP6 (ABCC6) detection in normal human tissues and tumors. Lab Invest. 2002 Apr;82(4):515-8.</citation>
    <PMID>11950908</PMID>
  </reference>
  <reference>
    <citation>Brown SJ, Talks SJ, Needham SJ, Taylor AE. Pseudoxanthoma elasticum: biopsy of clinically normal skin in the investigation of patients with angioid streaks. Br J Dermatol. 2007 Oct;157(4):748-51. Epub 2007 Jul 30.</citation>
    <PMID>17666106</PMID>
  </reference>
  <reference>
    <citation>Schröder F, Hausser I, Szliska C, Lawall H, Diehm C. Images in vascular medicine. Pseudoxanthoma elasticum: under-recognized cause of early onset peripheral arterial disease? Vasc Med. 2006 Nov;11(4):266-7.</citation>
    <PMID>17390553</PMID>
  </reference>
  <reference>
    <citation>Fabre B, Bayle P, Bazex J, Durand D, Lamant L, Chassaing N. Pseudoxanthoma elasticum and nephrolithiasis. J Eur Acad Dermatol Venereol. 2005 Mar;19(2):212-5.</citation>
    <PMID>15752294</PMID>
  </reference>
  <reference>
    <citation>Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet. 2005 Dec;42(12):881-92. Epub 2005 May 13. Review.</citation>
    <PMID>15894595</PMID>
  </reference>
  <reference>
    <citation>Laube S, Moss C. Pseudoxanthoma elasticum. Arch Dis Child. 2005 Jul;90(7):754-6. Review.</citation>
    <PMID>15970621</PMID>
  </reference>
  <reference>
    <citation>Li Q, Jiang Q, Pfendner E, Váradi A, Uitto J. Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms. Exp Dermatol. 2009 Jan;18(1):1-11. doi: 10.1111/j.1600-0625.2008.00795.x. Epub 2008 Oct 22. Review.</citation>
    <PMID>19054062</PMID>
  </reference>
  <reference>
    <citation>Lebwohl M, Schwartz E, Lemlich G, Lovelace O, Shaikh-Bahai F, Fleischmajer R. Abnormalities of connective tissue components in lesional and non-lesional tissue of patients with pseudoxanthoma elasticum. Arch Dermatol Res. 1993;285(3):121-6.</citation>
    <PMID>8503691</PMID>
  </reference>
  <reference>
    <citation>Plomp AS, Toonstra J, Bergen AA, van Dijk MR, de Jong PT. Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. Am J Med Genet A. 2010 Apr;152A(4):1049-58. doi: 10.1002/ajmg.a.33329. Review.</citation>
    <PMID>20358627</PMID>
  </reference>
  <reference>
    <citation>Quaglino D, Sartor L, Garbisa S, Boraldi F, Croce A, Passi A, De Luca G, Tiozzo R, Pasquali-Ronchetti I. Dermal fibroblasts from pseudoxanthoma elasticum patients have raised MMP-2 degradative potential. Biochim Biophys Acta. 2005 Jun 30;1741(1-2):42-7. Epub 2004 Oct 8.</citation>
    <PMID>15955448</PMID>
  </reference>
  <reference>
    <citation>Pasquali-Ronchetti I, Garcia-Fernandez MI, Boraldi F, Quaglino D, Gheduzzi D, De Vincenzi Paolinelli C, Tiozzo R, Bergamini S, Ceccarelli D, Muscatello U. Oxidative stress in fibroblasts from patients with pseudoxanthoma elasticum: possible role in the pathogenesis of clinical manifestations. J Pathol. 2006 Jan;208(1):54-61.</citation>
    <PMID>16261549</PMID>
  </reference>
  <reference>
    <citation>Quaglino D, Boraldi F, Barbieri D, Croce A, Tiozzo R, Pasquali Ronchetti I. Abnormal phenotype of in vitro dermal fibroblasts from patients with Pseudoxanthoma elasticum (PXE). Biochim Biophys Acta. 2000 Apr 15;1501(1):51-62.</citation>
    <PMID>10727849</PMID>
  </reference>
  <reference>
    <citation>Ronchetti I, Boraldi F, Annovi G, Cianciulli P, Quaglino D. Fibroblast involvement in soft connective tissue calcification. Front Genet. 2013 Mar 5;4:22. doi: 10.3389/fgene.2013.00022. eCollection 2013.</citation>
    <PMID>23467434</PMID>
  </reference>
  <reference>
    <citation>Boraldi F, Annovi G, Bartolomeo A, Quaglino D. Fibroblasts from patients affected by Pseudoxanthoma elasticum exhibit an altered PPi metabolism and are more responsive to pro-calcifying stimuli. J Dermatol Sci. 2014 Apr;74(1):72-80. doi: 10.1016/j.jdermsci.2013.12.008. Epub 2014 Jan 2.</citation>
    <PMID>24461675</PMID>
  </reference>
  <reference>
    <citation>Boraldi F, Bartolomeo A, Li Q, Uitto J, Quaglino D. Changes in dermal fibroblasts from Abcc6(-/-) mice are present before and after the onset of ectopic tissue mineralization. J Invest Dermatol. 2014 Jul;134(7):1855-1861. doi: 10.1038/jid.2014.88. Epub 2014 Feb 13.</citation>
    <PMID>24670382</PMID>
  </reference>
  <reference>
    <citation>Garcia-Fernandez MI, Gheduzzi D, Boraldi F, Paolinelli CD, Sanchez P, Valdivielso P, Morilla MJ, Quaglino D, Guerra D, Casolari S, Bercovitch L, Pasquali-Ronchetti I. Parameters of oxidative stress are present in the circulation of PXE patients. Biochim Biophys Acta. 2008 Jul-Aug;1782(7-8):474-81. doi: 10.1016/j.bbadis.2008.05.001. Epub 2008 May 10.</citation>
    <PMID>18513494</PMID>
  </reference>
  <reference>
    <citation>Morillo MJ, Mora J, Soler A, García-Campos JM, García-Fernández I, Sánchez P, Valdivieso P. [Retinal autofluorescence imaging in patients with pseudoxanthoma elasticum]. Arch Soc Esp Oftalmol. 2011 Jan;86(1):8-15. doi: 10.1016/j.oftal.2010.11.019. Epub 2011 Feb 20. Spanish.</citation>
    <PMID>21414524</PMID>
  </reference>
  <reference>
    <citation>Jiang Q, Endo M, Dibra F, Wang K, Uitto J. Pseudoxanthoma elasticum is a metabolic disease. J Invest Dermatol. 2009 Feb;129(2):348-54. doi: 10.1038/jid.2008.212. Epub 2008 Aug 14.</citation>
    <PMID>18685618</PMID>
  </reference>
  <reference>
    <citation>Uitto J, Li Q, Jiang Q. Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms. J Invest Dermatol. 2010 Mar;130(3):661-70. doi: 10.1038/jid.2009.411. Epub 2009 Dec 24.</citation>
    <PMID>20032990</PMID>
  </reference>
  <reference>
    <citation>Boraldi F, Garcia-Fernandez M, Paolinelli-Devincenzi C, Annovi G, Schurgers L, Vermeer C, Cianciulli P, Ronchetti I, Quaglino D. Ectopic calcification in β-thalassemia patients is associated with increased oxidative stress and lower MGP carboxylation. Biochim Biophys Acta. 2013 Dec;1832(12):2077-84. doi: 10.1016/j.bbadis.2013.07.017. Epub 2013 Jul 27.</citation>
    <PMID>23899606</PMID>
  </reference>
  <reference>
    <citation>Li Q, Jiang Q, Uitto J. Ectopic mineralization disorders of the extracellular matrix of connective tissue: molecular genetics and pathomechanisms of aberrant calcification. Matrix Biol. 2014 Jan;33:23-8. doi: 10.1016/j.matbio.2013.06.003. Epub 2013 Jul 25. Review.</citation>
    <PMID>23891698</PMID>
  </reference>
  <reference>
    <citation>Jansen RS, Küçükosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K. ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20206-11. doi: 10.1073/pnas.1319582110. Epub 2013 Nov 25.</citation>
    <PMID>24277820</PMID>
  </reference>
  <reference>
    <citation>Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Váradi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P, van de Wetering K. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1985-9. doi: 10.1161/ATVBAHA.114.304017. Epub 2014 Jun 26.</citation>
    <PMID>24969777</PMID>
  </reference>
  <reference>
    <citation>Moore SN, Tanner SB, Schoenecker JG. Bisphosphonates: from softening water to treating PXE. Cell Cycle. 2015;14(9):1354-5. doi: 10.1080/15384101.2015.1024585.</citation>
    <PMID>25894689</PMID>
  </reference>
  <reference>
    <citation>Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts MF, Millán JL. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res. 2007 Nov;22(11):1700-10.</citation>
    <PMID>17638573</PMID>
  </reference>
  <reference>
    <citation>Li Q, Sundberg JP, Levine MA, Terry SF, Uitto J. The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene. Cell Cycle. 2015;14(7):1082-9. doi: 10.1080/15384101.2015.1007809.</citation>
    <PMID>25607347</PMID>
  </reference>
  <reference>
    <citation>Millán JL (2006) APs as Physiological and Disease Markers. In Mammalian Alkaline Phosphatases, pp. 165-185: Wiley-VCH Verlag GmbH &amp; Co. KgaA</citation>
  </reference>
  <reference>
    <citation>Boraldi F, Annovi G, Guerra D, Paolinelli Devincenzi C, Garcia-Fernandez MI, Panico F, De Santis G, Tiozzo R, Ronchetti I, Quaglino D. Fibroblast protein profile analysis highlights the role of oxidative stress and vitamin K recycling in the pathogenesis of pseudoxanthoma elasticum. Proteomics Clin Appl. 2009 Sep;3(9):1084-98. doi: 10.1002/prca.200900007. Epub 2009 Aug 26.</citation>
    <PMID>21137008</PMID>
  </reference>
  <reference>
    <citation>Boraldi F, Quaglino D, Croce MA, Garcia Fernandez MI, Tiozzo R, Gheduzzi D, Bacchelli B, Pasquali Ronchetti I. Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. Matrix Biol. 2003 Nov;22(6):491-500.</citation>
    <PMID>14667841</PMID>
  </reference>
  <reference>
    <citation>Delomenède M, Buchet R, Mebarek S. Lansoprazole is an uncompetitive inhibitor of tissue-nonspecific alkaline phosphatase. Acta Biochim Pol. 2009;56(2):301-5. Epub 2009 Jun 18.</citation>
    <PMID>19543559</PMID>
  </reference>
  <reference>
    <citation>Matsunaga C, Izumi S, Furukubo T, Satoh M, Yamakawa T, Uchida T, Kadowaki D, Hirata S. Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy. Clin Nephrol. 2007 Aug;68(2):93-8.</citation>
    <PMID>17722708</PMID>
  </reference>
  <reference>
    <citation>O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant. 2010 Jan;25(1):187-91. doi: 10.1093/ndt/gfp362. Epub 2009 Jul 24.</citation>
    <PMID>19633093</PMID>
  </reference>
  <reference>
    <citation>Battisti V, Maders LD, Bagatini MD, Battisti IE, Bellé LP, Santos KF, Maldonado PA, Thomé GR, Schetinger MR, Morsch VM. Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in prostate cancer patients: influence of Gleason score, treatment and bone metastasis. Biomed Pharmacother. 2013 Apr;67(3):203-8. doi: 10.1016/j.biopha.2012.12.004. Epub 2012 Dec 26.</citation>
    <PMID>23433854</PMID>
  </reference>
  <reference>
    <citation>Sergienko E, Su Y, Chan X, Brown B, Hurder A, Narisawa S, Millán JL. Identification and characterization of novel tissue-nonspecific alkaline phosphatase inhibitors with diverse modes of action. J Biomol Screen. 2009 Aug;14(7):824-37. doi: 10.1177/1087057109338517. Epub 2009 Jun 25.</citation>
    <PMID>19556612</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grönblad-Stranberg Disease</keyword>
  <keyword>Pseudoxathoma Elasticum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoxanthoma Elasticum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

